The company plans to use parts of the proceeds from the offering to pay for the recent settlement with Illumina.

The company is developing a method that uses whole-genome sequencing to develop patient-specific assays for tracking tumor signals in the blood.

Researchers found that when combined into a risk score, heart disease loci identified in the general population were also associated with heart disease in type 2 diabetes.

A team led by Walter and Eliza Hall Institute researchers found that ovarian tumors with complete BRCA1 methylation and silencing were more susceptible to treatment.

The firm has been piecing together a collection of acquisitions over recent years that expand its presence in the genomics market, particularly custom oligos.

The 72-SNP score is for men of European ancestry who don't have mutations in high penetrance risk genes or mutations in genes associated with aggressive disease.

The companies are developing a risk model to predict the likelihood that a prostate cancer patient will develop advanced or metastatic disease.

Nature News reports that the bodies that award Nobel Prizes are making small changes aimed at increasing diversity among laureates.

Stat News reports that pharmacogenomics testing in psychiatry may be ahead of the science.

An economic crisis in Argentina has led to a decreased science budget, worrying researchers, according to ScienceInsider.

In Science this week: series of reviews about gene modification, and more.

The company had been warned in March that it failed to meet a listing requirement calling for a minimum $1 per share closing price of its common stock.

The new approval will allow the use of Qiagen's Therascreen EGFR RGQ PCR Kit as a companion diagnostic for Pfizer's Vizimpro in NSCLC patients.

Smaller multiplex molecular panels of five or fewer targets will be covered, while a determination of gastrointestinal panel coverage is expected soon.

The researchers characterized how gene therapy affects the immune cell repertoires and microbiomes of X-linked severe combined immunodeficiency patients.

The project aims to create a cancer genetics database specific to the Chinese population in order to facilitate cancer research and personalized treatment.

MNG Laboratories has launched the MNG Xpress Exome, a diagnostic exome sequencing test to identify mutations in Mendelian disorders. The test, which has a turnaround time of 10 to 14 days, costs $4,895 for a trio and $3,295 for proband-only testing.

Horizon Discovery launched its Myeloid DNA Reference Standard, a large cell-line derived myeloid cancer reference standard designed to enable faster, more reliable, and more cost-effective assay validation. The Myeloid DNA Reference Standard is latest addition to the company's portfolio of more than 100 reference standards, and has been developed using Horizon's specialist gene editing technology to contain 22 mutations across 19 genes that are commonly associated with myeloid cancer. This provides genetic testing laboratories and assay developers with a tool to effectively validate and optimize myeloid genetic tests with DNA of known genotype which closely mimics the genomic DNA format and mutations present in real patient samples. The Myeloid DNA Reference Standard contains variants in more genes than most clinical material, enabling quality assurance goals to be reached faster, the firm noted.

Sysmex Inostics, a subsidiary of Sysmex, has launched the OncoBeam EGFR Kit V2 for research use only in Europe and Asia. Replacing the firm's EGFR V1 kit, the V2 kit features workflow improvements, such as minimizing hands-on time and increasing efficiency. In addition, the kit covers substantially more mutations in the EGFR gene than its predecessor.

Sysmex's tool employs the firm's BEAMing technology to detect 36 cancer-relevant EGFR mutations present in ctDNA extracted from plasma, including sensitizing mutations like exon 19 deletions and L848R, as well as the T790M resistance mutation and multiple C797S variants. The assay combines emulsion-based PCR with flow cytometry to provide sensitive detection of rare mutant molecules. According to the firm, the assay requires a minimum of 2 ml of plasma to quickly deliver a comprehensive view of EGFR mutation status across all tumor cells. 

The company has developed a technology for isolating cancer DNA in urine along with specialized PCR assays to identify biomarkers that it believes will offer more accurate and sensitive detection of hepatocellular carcinoma.

These three loci implicated skeletal and spinal cord development-linked pathways in chronic back pain.

Using single-cell RNA sequencing and reporter lineage tracking, researchers delved into the cellular and molecular processes of axolotl limb regeneration.